Michael R. Betts
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Michael R. Betts has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Anne F. Peery
Department of Medicine, University of North Carolina, Chapel Hill, North Carolina
1 shared publication - Brigitte Allard
UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
1 shared publication - Camilla Tondello
Institute for Pharmacology and Toxicology, Pharmazentrum Frankfurt/ZAFES, Goethe University Frankfurt, Frankfurt, Germany
1 shared publication - Caroline Baker
Department of Medicine
1 shared publication - Christine Bender
Institute for Pharmacology and Toxicology, Pharmazentrum Frankfurt/ZAFES, Goethe University Frankfurt, Frankfurt, Germany
1 shared publication - Cory H. White
The Institute of Developmental Sciences, Human Development and Health, Faculty of Medicine University of Southampton
1 shared publication
Latest Publications
- Open Access
- 23 December 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (4)
Single-cell characterization of the gastrointestinal HIV reservoir reveals heterogeneous cellular phenotypes
Human gastrointestinal (GI) tissues are a major site of HIV-1 viral persistence, but the nature of the GI reservoir remains poorly described. To characterize the GI HIV reservoir, we profiled cells from GI tissue and matched PBMCs from 10 people with HIV on antiretroviral therapy using single-cell RNA sequencing. We identified distinct compartment-specific patterns of gene expression, highlighting key differences between blood and colon CD4 + T cell populations. vRNA + cells from both blood and GI tissue were heterogeneous and found in multiple subtypes of CD4 + T cells, although vRNA + cells were particularly enriched in cells with Th17 or Treg17 phenotypes. Transcriptomic comparison of HIV vRNA + and vRNA – T cells revealed 116 differentially expressed genes that were associated with HIV infection, including ZBED2 , MAF , and IL17F . These data provide what we believe to be new information regarding the GI-resident HIV reservoir and suggest that compartment-specific patterns of gene expression are associated with HIV infection.
- 23 December 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (4)
Open AccessSingle-cell characterization of the gastrointestinal HIV reservoir reveals heterogeneous cellular phenotypes
Human gastrointestinal (GI) tissues are a major site of HIV-1 viral persistence, but the nature of the GI reservoir remains poorly described. To characterize the GI HIV reservoir, we profiled cells from GI tissue and matched PBMCs from 10 people with HIV on antiretroviral therapy using single-cell RNA sequencing. We identified distinct compartment-specific patterns of gene expression, highlighting key differences between blood and colon CD4 + T cell populations. vRNA + cells from both blood and GI tissue were heterogeneous and found in multiple subtypes of CD4 + T cells, although vRNA + cells were particularly enriched in cells with Th17 or Treg17 phenotypes. Transcriptomic comparison of HIV vRNA + and vRNA – T cells revealed 116 differentially expressed genes that were associated with HIV infection, including ZBED2 , MAF , and IL17F . These data provide what we believe to be new information regarding the GI-resident HIV reservoir and suggest that compartment-specific patterns of gene expression are associated with HIV infection.
- Open Access
- 27 February 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (7)
The XCL1/XCR1 axis is upregulated in type 1 diabetes and aggravates its pathogenesis
Type 1 diabetes (T1D) is precipitated by the autoimmune destruction of the insulin-producing β cells in the pancreatic islets of Langerhans. Chemokines have been identified as major conductors of islet infiltration by autoaggressive leukocytes, including antigen-presenting cells and islet autoantigen–specific T cells. We have previously generated a road map of gene expression in the islet microenvironment during T1D in a mouse model and found that most of the chemokine axes are chronically upregulated during T1D. The XCL1/XCR1 chemokine axis is of particular interest, since XCR1 is exclusively expressed on conventional DCs type 1 (cDC1) that excel by their high capacity for T cell activation. Here, we demonstrate that cDC1-expressing XCR1 are present in and around the islets of patients with T1D and of individuals with islet autoantibody positivity. Furthermore, we show that XCL1 plays an important role in the attraction of highly potent DCs expressing XCR1 to the islets in an inducible mouse model for T1D. XCL1-deficient mice display a diminished infiltration of XCR1 + cDC1 and, subsequently, a reduced magnitude and activity of islet autoantigen–specific T cells, resulting in a profound decrease in T1D incidence. Interference with the XCL1/XCR1 chemokine axis might constitute a novel therapy for T1D.
- 27 February 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (7)
Open AccessThe XCL1/XCR1 axis is upregulated in type 1 diabetes and aggravates its pathogenesis
Type 1 diabetes (T1D) is precipitated by the autoimmune destruction of the insulin-producing β cells in the pancreatic islets of Langerhans. Chemokines have been identified as major conductors of islet infiltration by autoaggressive leukocytes, including antigen-presenting cells and islet autoantigen–specific T cells. We have previously generated a road map of gene expression in the islet microenvironment during T1D in a mouse model and found that most of the chemokine axes are chronically upregulated during T1D. The XCL1/XCR1 chemokine axis is of particular interest, since XCR1 is exclusively expressed on conventional DCs type 1 (cDC1) that excel by their high capacity for T cell activation. Here, we demonstrate that cDC1-expressing XCR1 are present in and around the islets of patients with T1D and of individuals with islet autoantibody positivity. Furthermore, we show that XCL1 plays an important role in the attraction of highly potent DCs expressing XCR1 to the islets in an inducible mouse model for T1D. XCL1-deficient mice display a diminished infiltration of XCR1 + cDC1 and, subsequently, a reduced magnitude and activity of islet autoantigen–specific T cells, resulting in a profound decrease in T1D incidence. Interference with the XCL1/XCR1 chemokine axis might constitute a novel therapy for T1D.